The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog

Meyer‐Lindenberg, Andrea; Wohlfarth, Kai; Switzer, Elinor

doi:10.1111/j.1751-0813.2003.tb12503.x

Cited by 13 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most effective safe dose of botulinum toxin A in human beings appears to be 12 mu/kg (Gooch and Patton 2004). The veterinary therapeutic use of botulinum toxin A is limited to one case report in the dog (Meyer‐Lindenberg and others 2003) and therefore the optimal dose for use in small animals has not yet been fully determined. A dose of 10 mu/kg was used in this case as this appeared to produce the desired effects in dogs in a clinical research report (Childers and others 1998).…”

Section: Discussionmentioning

confidence: 99%

Partial tarsal arthrodesis and botulinum toxin A injection for correction of tarsal arthrogryposis in a cat

Bright

Girling

O'Neill

et al. 2006

J of Small Animal Practice

View full text Add to dashboard Cite

An 11-week-old, domestic shorthair cat was presented for evaluation of a congenital right tarsal deformity. The cat was non-weightbearing lame on the right hindlimb. There was severe tarsal hyperextension and concurrent spasticity/contracture/shortening of the gastrocnemius muscle-tendon. The cat was otherwise healthy. Radiographically there was luxation of the proximal intertarsal joint and talocrural hyperextension. Treatment with 10 mu/kg botulinum toxin A (Botox; Allergan) intramuscular injections directly into the gastrocnemius muscle and passive physiotherapy marginally improved the range of motion in the talocrural joint. Definitive surgical treatment with partial tarsal arthodesis produced an excellent clinical outcome. This case report demonstrates the successful treatment of a severe congenital tarsal abnormality and also documents the first clinical use of botulinum toxin in a feline patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Partial tarsal arthrodesis and botulinum toxin A injection for correction of tarsal arthrogryposis in a cat

Bright

Girling

O'Neill

et al. 2006

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…A clinical case of blepharospasm in a Great Dane dog treated with BoNT-A was described by Meyer-Lindenberg et al (2003). BoNT-A (Dysport®, Ipsen Pharma, Ettlingen, Germany) was injected subcutaneously in the dosage of 200 MU, in the six sites per eye in the area of orbicularis oris muscle.…”

Section: Bont As Antispasmodic Agent In Dogs and Catsmentioning

confidence: 99%

Botulinum toxin: From the natural cause of botulism to an emerging therapeutic in veterinary medicine

2022

Veterinaria

View full text Add to dashboard Cite

show abstract

“…Focal dystonia can be experimentally induced in animals ( 65 ) and cases of focal muscle contractions in domestic animals may resemble human focal dystonia. Meyer-Lindenberg et al ( 66 ) described an interesting case of severe bilateral blepharospasm in a Great Dane dog. Following a moderate bilateral ectropium, blepharospasm (which was intensified by stress and bright light) could be observed from an age of 8 months.…”

Section: Hyperkinetic Movement Disorders In Domestic Animals: Common mentioning

confidence: 99%

“…EMG revealed complex high frequency discharges of the orbicularis oculi muscle. Finally, subcutaneous injections of BoNT in the area of the orbicularis oculi muscle resulted in disappearance of blepharospasm for 3–4 months ( 66 ). As observed in this dog, eye disorders commonly also precede human blepharospasm which is responsive to BoNT ( 63 ).…”

Section: Hyperkinetic Movement Disorders In Domestic Animals: Common mentioning

confidence: 99%

Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias

et al. 2015

View full text Add to dashboard Cite

Dystonia is defined as a neurological syndrome characterized by involuntary sustained or intermittent muscle contractions causing twisting, often repetitive movements, and postures. Paroxysmal dyskinesias are episodic movement disorders encompassing dystonia, chorea, athetosis, and ballism in conscious individuals. Several decades of research have enhanced the understanding of the etiology of human dystonia and dyskinesias that are associated with dystonia, but the pathophysiology remains largely unknown. The spontaneous occurrence of hereditary dystonia and paroxysmal dyskinesia is well documented in rodents used as animal models in basic dystonia research. Several hyperkinetic movement disorders, described in dogs, horses and cattle, show similarities to these human movement disorders. Although dystonia is regarded as the third most common movement disorder in humans, it is often misdiagnosed because of the heterogeneity of etiology and clinical presentation. Since these conditions are poorly known in veterinary practice, their prevalence may be underestimated in veterinary medicine. In order to attract attention to these movement disorders, i.e., dystonia and paroxysmal dyskinesias associated with dystonia, and to enhance interest in translational research, this review gives a brief overview of the current literature regarding dystonia/paroxysmal dyskinesia in humans and summarizes similar hereditary movement disorders reported in domestic animals.

show abstract

The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog

Cited by 13 publications

References 9 publications

Partial tarsal arthrodesis and botulinum toxin A injection for correction of tarsal arthrogryposis in a cat

Partial tarsal arthrodesis and botulinum toxin A injection for correction of tarsal arthrogryposis in a cat

Botulinum toxin: From the natural cause of botulism to an emerging therapeutic in veterinary medicine

Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias

Contact Info

Product

Resources

About